Omeprazol Atb (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Atb, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal disorders in adults and children.

GNH USA supplies Omeprazol Atb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric proton pump to lower acid secretion, making it useful for several acid‑related conditions. - Gastroesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by decreasing reflux‑inducing acid. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence by maintaining a less acidic gastric environment. - Helicobacter pylori eradication: enhances the effectiveness of antibiotic regimens by creating a less hostile stomach pH. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Adverse reactions may occur with omeprazole use.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may be transient. - Nausea: feeling of stomach upset, sometimes accompanied by vomiting. - Abdominal pain: discomfort or cramps in the stomach area. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Stevens‑Johnson syndrome: painful skin lesions and mucosal involvement. - Liver enzyme elevation: abnormal hepatic function tests. - Hypomagnesemia: low magnesium levels causing muscle cramps or arrhythmias. - Interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy, consider patient‑specific factors and safety measures. - Renal function assessment: adjust use in patients with severe renal impairment. - Hepatic status evaluation: monitor liver function in those with existing liver disease. - Elderly patients: start with the lowest effective dose and monitor for adverse effects. - Magnesium monitoring: check serum magnesium during prolonged therapy. - Discontinuation guidance: avoid abrupt cessation after long‑term use to prevent rebound acid hypersecretion. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the metabolism of several co‑administered drugs.

Major Interactions (Avoid): - Clarithromycin: increased risk of cardiac arrhythmias due to QT prolongation. - Ketoconazole: reduced antifungal absorption and efficacy. - Atazanavir: markedly decreased antiretroviral plasma concentrations.

Moderate Interactions (Monitor Closely): - Phenytoin: reduced phenytoin levels may diminish seizure control. - Carbamazepine: decreased carbamazepine exposure requiring dose adjustment. - Digoxin: increased digoxin levels may necessitate serum monitoring. - Methotrexate: higher methotrexate concentrations can raise toxicity risk.